Accurate assessment of idiopathic pulmonary fibrosis (IPF) disease severity is integral to the
care provided to patients with IPF. However, to date, there are no generally accepted or …

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …

Rationale: Sequence variation, methylation differences, and transcriptional changes in
desmoplakin (DSP) have been observed in patients with idiopathic pulmonary fibrosis (IPF) …

Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of~ 3
years. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease …

Fibrosis, a characteristic of all chronic kidney diseases, is now recognized to be an
independent predictor of disease progression. Deposition of pathological matrix in the walls …

Background Physical activity (PA) is associated with disease severity in idiopathic
pulmonary fibrosis (IPF), but longitudinal studies evaluating its prognostic value and …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis. In the last
decades pirfenidone an anti-inflammatory and anti-fibrotic agent has shown benefit in inhibit …

Background Mortality is an impractical primary endpoint for clinical trials in patients with
idiopathic pulmonary fibrosis who have mild-to-moderate physiological impairment because …

Abstract Background Matrix metalloproteinases (MMPs) are believed to be involved in the
pathogenesis of idiopathic pulmonary fibrosis (IPF), and MMP-7 has been described as a …

Idiopathic pulmonary fibrosis (IPF) is the severest form of idiopathic interstitial pneumonia,
with a median survival time estimated at 2–5 years from the time of diagnosis. It occurs …